(DNLI) Denali Therapeutics - Ratings and Ratios
Alzheimer, Parkinson, ALS, Lysosomal Storage
DNLI EPS (Earnings per Share)
DNLI Revenue
Description: DNLI Denali Therapeutics
Denali Therapeutics Inc (NASDAQ:DNLI) is a biotechnology company listed on the NASDAQ stock exchange, operating in the biotechnology sub-industry. The companys stock is classified as a common stock and is of US origin.
To assess the companys financial health, we can look at its market capitalization, which stands at approximately $1.955 billion. The absence of a price-to-earnings (P/E) ratio, both current and forward, suggests that the company is currently not profitable, which is not uncommon for companies in the biotechnology sector that are often in the development phase. The return on equity (RoE) is negative at -35.90%, indicating that the company is not generating profits from shareholders equity.
Key economic drivers for Denali Therapeutics include the success of its drug pipeline, particularly in the treatment of neurodegenerative diseases, and the ability to secure funding or partnerships to support its research and development activities. Key performance indicators (KPIs) to watch include the progress of its clinical trials, regulatory approvals, and the companys cash burn rate, which will be crucial in determining its ability to continue operations without additional capital infusion.
From a trading perspective, the stocks volatility, as indicated by its average true range (ATR) and beta, suggests that it is relatively sensitive to market movements, with a beta of 1.328 indicating that it is more volatile than the overall market. Investors should also monitor the companys cash position and funding requirements to assess the risk of dilution or financial distress.
The quarterly tax provision is an important aspect to analyze as it can provide insights into the companys financial performance and tax obligations. A thorough examination of this provision can reveal the companys effective tax rate, any tax loss carryforwards, and the impact of tax on its net income or loss.
DNLI Stock Overview
| Market Cap in USD | 2,256m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2017-12-08 |
DNLI Stock Ratings
| Growth Rating | -85.6% |
| Fundamental | 14.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -63.5% |
| Analyst Rating | 4.79 of 5 |
DNLI Dividends
Currently no dividends paidDNLI Growth Ratios
| Growth Correlation 3m | 40.5% |
| Growth Correlation 12m | -82% |
| Growth Correlation 5y | -89.2% |
| CAGR 5y | -24.21% |
| CAGR/Max DD 3y | -0.37 |
| CAGR/Mean DD 3y | -0.71 |
| Sharpe Ratio 12m | -0.80 |
| Alpha | -71.60 |
| Beta | 0.970 |
| Volatility | 54.97% |
| Current Volume | 1643.9k |
| Average Volume 20d | 1599.2k |
| Stop Loss | 12.2 (-7.3%) |
| Signal | -1.79 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-479.0m TTM) > 0 and > 6% of Revenue (6% = -28.6m TTM) |
| FCFTA -0.31 (>2.0%) and ΔFCFTA -6.49pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -177.2% (prev -281.1%; Δ 103.8pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.30 (>3.0%) and CFO -349.6m > Net Income -479.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 10.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (171.4m) change vs 12m ago 1.55% (target <= -2.0% for YES) |
| Gross Margin 100.6% (prev 102.8%; Δ -2.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover -35.67% (prev -20.22%; Δ -15.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -16.44
| (A) 0.72 = (Total Current Assets 934.7m - Total Current Liabilities 91.1m) / Total Assets 1.17b |
| (B) -1.54 = Retained Earnings (Balance) -1.80b / Total Assets 1.17b |
| warn (B) unusual magnitude: -1.54 — check mapping/units |
| (C) -0.39 = EBIT TTM -522.7m / Avg Total Assets 1.33b |
| (D) -12.88 = Book Value of Equity -1.79b / Total Liabilities 139.2m |
| Total Rating: -16.44 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 14.91
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -25.71% = -5.0 |
| 3. FCF Margin -76.39% = -7.50 |
| 4. Debt/Equity 0.06 = 2.50 |
| 5. Debt/Ebitda -0.11 = -2.50 |
| 6. ROIC - WACC -54.58% = -12.50 |
| 7. RoE -40.79% = -2.50 |
| 8. Rev. Trend -43.79% = -2.19 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend -15.86% = -0.40 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of DNLI shares?
Over the past week, the price has changed by -15.10%, over one month by -10.48%, over three months by -9.99% and over the past year by -56.61%.
Is Denali Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DNLI is around 8.56 USD . This means that DNLI is currently overvalued and has a potential downside of -34.95%.
Is DNLI a buy, sell or hold?
- Strong Buy: 15
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DNLI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 31.5 | 139.4% |
| Analysts Target Price | 31.5 | 139.4% |
| ValueRay Target Price | 9.7 | -26.4% |
Last update: 2025-09-08 04:36
DNLI Fundamental Data Overview
CCE Cash And Equivalents = 899.0m USD (Cash And Short Term Investments, last quarter)
Revenue TTM is 0, using Net Income TTM -479.0m + Cost of Revenue 3.04m = -476.0m USD
P/S = 3643.6484
P/B = 2.1966
Beta = 1.233
Revenue TTM = -476.0m USD
EBIT TTM = -522.7m USD
EBITDA TTM = -511.6m USD
Long Term Debt = 48.1m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 8.87m USD (from shortTermDebt, last quarter)
Debt = 57.0m USD (Calculated: Short Term 8.87m + Long Term 48.1m)
Net Debt = -94.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.41b USD (2.26b + Debt 57.0m - CCE 899.0m)
Interest Coverage Ratio = unknown (Ebit TTM -522.7m / Interest Expense TTM 0.0)
FCF Yield = -25.71% (FCF TTM -363.6m / Enterprise Value 1.41b)
FCF Margin = -76.39% (FCF TTM -363.6m / Revenue TTM -476.0m)
Net Margin = -100.6% (Net Income TTM -479.0m / Revenue TTM -476.0m)
Gross Margin = -100.6% ((Revenue TTM -476.0m - Cost of Revenue TTM 3.04m) / Revenue TTM)
Tobins Q-Ratio = -0.79 (set to none) (Enterprise Value 1.41b / Book Value Of Equity -1.79b)
Interest Expense / Debt = 36.98% (Interest Expense 21.1m / Debt 57.0m)
Taxrate = 21.0% (US default)
NOPAT = -522.7m (EBIT -522.7m, no tax applied on loss)
Current Ratio = 10.27 (Total Current Assets 934.7m / Total Current Liabilities 91.1m)
Debt / Equity = 0.06 (Debt 57.0m / last Quarter total Stockholder Equity 1.03b)
Debt / EBITDA = -0.11 (Net Debt -94.6m / EBITDA -511.6m)
Debt / FCF = -0.16 (Debt 57.0m / FCF TTM -363.6m)
Total Stockholder Equity = 1.17b (last 4 quarters mean)
RoA = -41.08% (Net Income -479.0m, Total Assets 1.17b )
RoE = -40.79% (Net Income TTM -479.0m / Total Stockholder Equity 1.17b)
RoCE = -42.76% (Ebit -522.7m / (Equity 1.17b + L.T.Debt 48.1m))
RoIC = -44.51% (NOPAT -522.7m / Invested Capital 1.17b)
WACC = 10.07% (E(2.26b)/V(2.31b) * Re(9.59%)) + (D(57.0m)/V(2.31b) * Rd(36.98%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 93.94 | Cagr: 3.03%
Discount Rate = 9.59% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -363.6m)
Revenue Correlation: -43.79 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: 168.6
EPS Correlation: -15.86 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -0.10
Additional Sources for DNLI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle